Cost-effectiveness of fracture prevention in men who receive androgen deprivation therapy for localized prostate cancer Academic Article uri icon

Overview

MeSH Major

  • Alendronate
  • Androgen Antagonists
  • Antineoplastic Agents
  • Bone Density Conservation Agents
  • Hip Fractures
  • Orchiectomy
  • Prostatic Neoplasms

abstract

  • In patients starting adjuvant ADT for locally advanced or high-risk localized prostate cancer, a BMD test followed by selective alendronate for those with osteoporosis is a cost-effective use of resources. Routine use of alendronate without a BMD test is justifiable in patients at higher risk for hip fractures.

publication date

  • May 18, 2010

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC5468170

PubMed ID

  • 20479027

Additional Document Info

start page

  • 621

end page

  • 9

volume

  • 152

number

  • 10